GlaxoSmithKline Grows Revenue, But PAT Hits Declining Stage

GlaxoSmithKline reported revenue growth for the third quarter of 2020, as the Pharmaceutical company was able to reduce its cost of production during the same period. This reflected in GlaxoSmithKline's profit grossed within the period of Q3 this year.

In the financial statement for 2020 third-quarter released by the company, AllNews gathered that GlaxoSmithKline's revenue shot up to NGN6.01 billion in Q3 this year, rising above the NGN5.95 billion it generated in the corresponding period of 2019 Q3.

The company's earnings for the period under review were assisted by the drop in the cost of production of its pharmaceutical products. It was reported that the cost of production sits at NGN4.49 billion, drastically lower than the NGN4.80 billion the company reported for 2019 Q3.

READ ALSO: Controversy: Sanwo-Olu, LCC Contradict Each Other Over Lekki Massacre

The reduction in the cost of production could be said to have played a role in the profit grossed for 2020 third-quarter, which was at NGN1.51 billion, surpassing the NGN1.14 billion it grossed as profit during the corresponding period of 2019 third-quarter.

However, during the Q3 2020 period, which falls between July to September, GlaxoSmithKline reported that its Profit Before Tax hit NGN61.80 million, failing to surpass the NGN81.52 million the company reported in the corresponding period of Q3 2019.

The same fate met the Profit After Tax of 2020 third-quarter, which GlaxoSmithKline reported to have reached NGN42.02 million, way lower than the NGN54.97 million of 2019 third-quarter, which is the corresponding period.